Hatch Biofund Management

What Hatch Biofund Management does

Hatch Biofund Management is a privately held life sciences venture capital firm headquartered in Doylestown, Pennsylvania with a satellite office at B+Labs in Philadelphia, employing 1-10 people. The firm provides early-stage capital to private companies developing therapeutics and vaccines for human use, pairing investment with access to deep industry expertise and physical platforms including incubator space at the Pennsylvania Biotechnology Center (PABC) and B+Labs. Its business model is a traditional early-stage venture fund: it deploys limited-partner capital into portfolio companies and earns returns through exits, while relying on management fees and carried interest as standard fund economics. Hatch is consistently structured as a co-investor rather than lead, with disclosed check sizes ranging from $250,000 (Hula Therapeutics, 2024) to participation in a $97 million Series A (Latus Bio, 2026).

The firm is differentiated operationally by an unusually deep strategic partner network for a fund of its size, including a core alliance with Daiichi Sankyo (a 19,700-employee global pharmaceutical company), Brandywine Realty Trust (which provides the B+Labs incubator ecosystem), the Baruch S. Blumberg Institute, the Hepatitis B Foundation, and the Pennsylvania Biotechnology Center. Leadership is concentrated in three named individuals: Managing Partner Lorenzo Pellegrini, Ph.D. (Wharton MBA, founder/co-founder of six biotech companies, prior Partner at Care Capital, founder and former CEO of Palladio Biosciences); Founder and Advisor Louis P. Kassa III, MPA (CEO of PABC, the Hepatitis B Foundation, and the Blumberg Institute); and Advisor Timothy M. Block, Ph.D. (co-founder and President Emeritus of the same three entities, US National Academy of Inventors member, co-inventor on 20 issued patents).

The disclosed portfolio of six companies spans diverse therapeutic modalities: Optimeos Life Sciences (Princeton spinout, nanoparticle drug delivery via Coated Inverse Nanocarriers), Vittoria Biotherapeutics (CAR-T cell therapies, Senza5 platform), Latus Bio (AAV gene therapy), Hula Therapeutics (immunotherapy), MasterSwitch Bio (mRNA therapy), and Ladder Bio (Spiroligomer platform). Revenue, AUM, fund size, LP composition, and founding date are not publicly disclosed. Marketing and investor relations are supported by standard digital analytics (Google Analytics, Hotjar, Meta Pixel) and a direct website contact channel.

Name

Hatch Biofund Management

Legal name

Hatch Biofund

Website

https://hatchbiofund.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Hatch Biofund Management is a privately held life sciences venture capital firm in the Philadelphia region that provides early-stage capital, industry expertise, and incubator access to therapeutics and vaccine companies through its PABC, B+Labs, and Daiichi Sankyo partner network.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA)

Keywords

• Life sciences venture capital
• Biotechnology early-stage investing
• Therapeutics seed funding
• Biotech startup capital
• Venture capital management

Headquarters

HQ city

Doylestown

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure

Marketing channels4 records

Core offering

Hatch Biofund is a life sciences venture capital firm that provides early-stage capital to private companies developing therapeutics and vaccines for human use. In addition to funding, the firm offers portfolio companies access to deep industry expertise and physical platforms, including incubator lab space through partnerships with the Pennsylvania Biotechnology Center and B+Labs. The firm invests across all development stages and treatment modalities, with a current portfolio of six companies.

Product overview

Hatch Biofund is a life sciences venture capital firm that operates as a single unified investment offering rather than a platform-plus-modules architecture. The firm provides early-stage capital to life science companies, focusing exclusively on private companies developing therapeutics and vaccines for human use across all development stages and treatment modalities. The portfolio includes six portfolio companies: Optimeos Life Sciences (nanoparticle drug delivery), Vittoria Biotherapeutics (CAR T cell therapies with Senza5™ platform), Latus Bio (AAV gene therapy), Hula Therapeutics (immunotherapy), MasterSwitch Bio (mRNA therapy), and Ladder Bio (Spiroligomer™ platform).

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Capital Investment Services Hatch Biofund provides early-stage capital to promising life science companies developing therapeutics and vaccines for human use, along with access to deep industry expertise and physical platforms to help them realize their missions.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core.

• Brandywine Realty TrustcoreStrategic or Co-development PartnerSelf-administered and self-managed real estate investment trust engaged in acquisition, development, and management of office and mixed-use properties. One of the largest, publicly traded, full-service, integrated real estate companies in the US with core focus in Philadelphia, Austin, and Washington D.C. markets. Provides life science ecosystem and incubator space (B+Labs) for Hatch portfolio companies.
• Daiichi SankyocoreStrategic or Co-development PartnerInnovative global healthcare company contributing to sustainable development of society that discovers, develops, and delivers new standards of care. Legacy of innovation since 1899 with presence in 32 countries and 19,700+ employees. Leverages world-class science and technology to create new modalities and innovative medicines for cancer, cardiovascular, and other diseases with high unmet medical need.
• Baruch S. Blumberg InstitutecoreStrategic or Co-development PartnerIndependent, nonprofit research organization launched in 2003 by the Hepatitis B Foundation. One of the nation's leading centers for translational research in hepatitis B and liver cancer. Supports drug discovery, biomarker discovery and translational biotechnology around common research themes such as chronic hepatitis, liver disease and liver cancer.
• The Hepatitis B FoundationcoreStrategic or Co-development PartnerThe nation's leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving quality of life for those affected worldwide through research, education and patient advocacy. Founded in 1991, based in Doylestown, PA with offices in Washington D.C. and Philadelphia.
• B+LabscoreStrategic or Co-development PartnerNewly-constructed, state-of-the-art 50,000 sqft life sciences incubator in the heart of University City, Philadelphia. Powered by the Pennsylvania Biotechnology Center (PABC), provides flexible, plug & play lab and research space within a specialized network of resources, programming, and expertise. Part of Brandywine's Life Science ecosystem.
• Pennsylvania Biotechnology CentercoreStrategic or Co-development PartnerNonprofit life sciences incubator-accelerator located in Doylestown, PA in the heart of the Philadelphia-New Jersey pharma belt. Offers state-of-the-art laboratory and office space to 40+ early stage biotech companies. Uses highly successful services-based approach. To date, more than 75 companies have called PABC their home. PABC tenants account for 17% of all NIH SBIR grants awarded in Pennsylvania.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• RA Capital Management: Healthcare-focused investment manager with dedicated life sciences venture activity; competes for similar therapeutic assets but at materially larger check sizes and broader scale.
• Atlas Venture: Prominent early-stage biotech venture firm that builds companies around novel therapeutics, comparable in investment stage and therapeutic focus but with a far larger fund and broader geographic reach.
• 5AM Ventures: Established early-stage life sciences venture firm investing in platform technologies and therapeutics; larger and more diversified than Hatch but addresses the same founder-investor dynamic.
• OrbiMed: One of the largest healthcare-dedicated investment firms globally, with dedicated venture activity in therapeutics at comparable early stages but with much greater capital and global reach.

Emerging players

• IndieBio: Biotech accelerator providing early-stage capital, lab infrastructure, and programming to biology-driven startups, comparable in the combined capital-plus-platform offering though typically earlier and at smaller scale.

Direct peers

• Cure Ventures: Early-stage life sciences venture firm investing in therapeutics and platform technologies with hands-on company-building support, structurally analogous to Hatch's capital-plus-expertise offering.
• Mission BioCapital: Early-stage venture firm focused on breakthrough life sciences platforms and therapeutics, with comparable fund size and founder-collaboration model.
• BioAdvance: Philadelphia-based active investor in early-stage life sciences companies in the Greater Philadelphia region, with a comparable focus on therapeutics and platform technologies emerging from the Mid-Atlantic biotech ecosystem.
• MRL Ventures Fund: Early-stage, therapeutics-focused venture fund that invests in and helps build biotech startups, with a similar small-team model and emphasis on founder collaboration around capital efficiency.

Others

• Daiichi Sankyo Venture Investments: Strategic corporate venture arm of Daiichi Sankyo, which is a core strategic partner of Hatch; invested in similar therapeutic modalities and could serve as a co-investor, follow-on capital provider, or acquirer for Hatch portfolio companies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/hatchbiofund

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hatch Biofund Management